Yarrow Bioscience, Inc.
YARWNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for YARW. That does not mean none is planned.
Get an email about YARW's next catalysts
Track Yarrow Bioscience (YARW) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
YARW Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
FMX103 minocycline foam
Facial Papulopustular Rosacea
FMX103
Papulopustular Rosacea
FMX101
Acne Vulgaris
FMX-101, minocycline foam
Acne Vulgaris
YB-101
Graves' Disease
Topical Minocycline Foam FXFM244
Acne Vulgaris
serlopitant
Prurigo Nodularis
VYN201 Gel
Non-segmental Vitiligo
FMX114
Atopic Dermatitis
FMX-103
Rosacea
Serlopitant Tablet
Epidermolysis Bullosa
ARK-E021
Acne Vulgaris
Serlopitant High Dose
Pruritus
FDX104 (Doxycycline)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
VPD-737
Chronic Pruritus
MK0594
Urinary Incontinence
Minocycline Foam
Acne Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FMX103 minocycline foam | Phase 3 | Facial Papulopustular Rosacea | - | - |
FMX103 | Phase 3 | Papulopustular Rosacea | - | - |
FMX101 | Phase 3 | Acne Vulgaris | - | - |
FMX-101, minocycline foam | Phase 3 | Acne Vulgaris | - | - |
YB-101 | Phase 2 | Graves' Disease | - | - |
Topical Minocycline Foam FXFM244 | Phase 2 | Acne Vulgaris | - | - |
serlopitant | Phase 2 | Prurigo Nodularis | - | - |
VYN201 Gel | Phase 2 | Non-segmental Vitiligo | - | - |
FMX114 | Phase 2 | Atopic Dermatitis | - | - |
FMX-103 | Phase 2 | Rosacea | - | - |
Serlopitant Tablet | Phase 2 | Epidermolysis Bullosa | - | - |
ARK-E021 | Phase 2 | Acne Vulgaris | - | - |
Serlopitant High Dose | Phase 2 | Pruritus | - | - |
FDX104 (Doxycycline) | Phase 2 | Rash Due to Epidermal Growth Factor Receptor Inhibitors | - | - |
VPD-737 | Phase 2 | Chronic Pruritus | - | - |
MK0594 | Phase 2 | Urinary Incontinence | - | - |
Minocycline Foam | Phase 2 | Acne Vulgaris | - | - |
Acne Vulgaris
1 drug in this indication
Urinary Incontinence
1 drug in this indication
Chronic Pruritus
1 drug in this indication
Pruritus
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Yarrow Bioscience, Inc.'s drug pipeline?→
CatalystAlert tracks 17 drug candidates in Yarrow Bioscience, Inc.'s (YARW) pipeline across Phase 3, Phase 2. Its lead program is FMX-101, minocycline foam (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Yarrow Bioscience, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Yarrow Bioscience, Inc. (YARW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track YARW biotech catalysts?→
Add YARW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Yarrow Bioscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.